Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients

Journal of Heart and Lung Transplantation

Volumn 21, Issue 12, 2002, Pages 1274-1282

  Bhorade, Sangeeta M ^a   Lurain, Nell S ^b   Jordan, Ashby ^a   Leischner, Julie ^a   Villanueva, Jaime ^a   Durazo, Ramon ^a   Creech, Steve ^a   Vigneswaran, Wickii T ^a   Garrity, Edward R ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; GANCICLOVIR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD CULTURE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG USE; FEMALE; GENOTYPE; GRAFT REJECTION; HIGH RISK POPULATION; HUMAN; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING; SURVIVAL; TREATMENT OUTCOME;

ADULT; CASE-CONTROL STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LUNG TRANSPLANTATION; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; PROBABILITY; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TRANSPLANTATION IMMUNOLOGY;

EID: 0036906529     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)00463-1     Document Type: Article

References (29)

1. Ettinger N.A., Bailey T.C., Trulock E.P., et al. Cytomegalovirus infection and pneumonitis impact after isolated lung transplantation . Am Rev Respir Dis 147:1993;1017-1023.
2. Duncan S.R., Grgurich W.F., Iacono A.T., et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 150:1994;146-152.
3. Fishman J.A., Rubin R.H. Infection in organ transplant recipients. N Engl J Med. 338:1998;1741-1751.
4. Keenan R.J., Lega M.E., Dummer J.S., et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation. 51:1991;433-438.
5. Duncan S.R., Paradis I.L., Yousem S.A., et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis. 146:1992;1419-1425.
6. Husni R.N., Gordon S.M., Longworth D.L., et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis. 26:1998;753-755.
7. Patel R., Snydman D.R., Rubin R.H., et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation. 61:1996;1279.
8. Maurer J.R., Snell G., deHoyos A., et al. Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens. Transplant Proc. 25:1993;1434-1435.
9. Hertz MI, Jordan C, Savik SK, Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant 1998;17:913-20.
10. Egan J.J., Lomax J., Barber L., et al. Preemptive treatment for the prevention of cytomegalovirus disease in lung and heart transplant recipients. Transplantation. 65:1998;747-752.
11. Biron K., Fyfe J., Stanat S., et al. A human cytomegalovirus mutant resistant to the nucleoside analogue 9-(2-hydroxyl-1-(hydroxymethyl)ethoxy)methyl)-guanine (BW B759U) induces reduced levels of BW B759U. Proc Natl Acad Sci USA. 83:1986;8769.
12. Drew W.L., Miner R.C., Busch D.F., et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 163:1991;716-719.
13. Jabs D.A., Enger C., Dunn J.P., et al. Cytomegalovirus retinitis and viral resistance ganciclovir resistance . J Infect Dis. 177:1998;770-773.
14. Lurain N.S., Ammons H.C., Kapell K.S., et al. Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation. 62:1996;497-502.
15. Erice A., Chou S., Biron K.K., et al. Progressive disease due to ganciclovir resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 320:1986;289-293.
16. Mendez J.C., Sia I.G., Tau K.R., et al. Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. Transplantation. 67:1999;755-757.
17. Baldanti F., Simoncini L., Sarasini A., et al. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation. 66:1998;324-329.
18. Alain S., Honderlick P., Grenet D., et al. Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. Transplantation. 63:1997;1533-1536.
19. Erice A., Gil-Roda C., Perez J.L., et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis. 175:1997;1087-1092.
20. Lawrence D.W. Ganciclovir resistance a matter of time and titre . Lancet. 356:2000;609-610.
21. Limaye A.P., Corey L., Koelle D.M., et al. Emergence of ganciclovir resistant cytomegalovirus disease among recipients of solid organ transplants. Lancet. 356:2000;645-649.
22. Kruger R.M., Shannon W.D., Arens M.Q., et al. The impact of ganciclovir resistant cytomegalovirus infection after lung transplantation. Transplantation. 68:1999;1272-1279.
23. Chou S. Antiviral drug resistance in human cytomegalovirus. Transplant Infect Dis. 1:1999;105-114.
24. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev. 12:1999;286-297.
25. Yousem S., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection lung rejection study group . J Heart Lung Transplant. 15:1996;1-15.
26. Cooper J.D., Billingham M., Egan T., et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant. 12:1993;713-716.
27. Ghisetti V., Barbui A., Pittaluga F., et al. Quantitation of human Cytomegalovirus DNA in peripheral blood leukocytes of heart transplant recipients relationship with pp65 antigenemia and antiviral therapy . Clin Microbiol Infect. 5:1999;23-31.
28. van den Berg A.P., van der Bij W., van Son W.J., et al. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation a report of 130 consecutive patients . Transplantation. 48:1989;991-995.
29. Landry M.L., Stanat S., Biron K., et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother. 44:2000;688-692.